Mara Goldstein
Stock Analyst at Mizuho
(2.51)
# 2,311
Out of 5,148 analysts
70
Total ratings
46.15%
Success rate
14.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $410 → $600 | $22.14 | +2,610.03% | 2 | Jan 27, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $8.68 | +245.62% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $3.79 | +163.85% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $5.82 | +37.46% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $23.94 | +75.44% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $12.28 | +307.17% | 2 | Jan 22, 2024 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $100.04 | -23.03% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $14.53 | -51.82% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.50 | +433.33% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $68.36 | +31.66% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $17.89 | -80.44% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.70 | +21,076.47% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $5.00 | +300.00% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $121.41 | +7.08% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $5.34 | -62.55% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.67 | +618.56% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $61.43 | -67.44% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.57 | +534.08% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.00 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $6.47 | +116.38% | 1 | Oct 12, 2017 |
Syndax Pharmaceuticals
Jan 27, 2026
Maintains: Outperform
Price Target: $410 → $600
Current: $22.14
Upside: +2,610.03%
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $8.68
Upside: +245.62%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $3.79
Upside: +163.85%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.82
Upside: +37.46%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $23.94
Upside: +75.44%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $12.28
Upside: +307.17%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $100.04
Upside: -23.03%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $14.53
Upside: -51.82%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.50
Upside: +433.33%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $68.36
Upside: +31.66%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $17.89
Upside: -80.44%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.70
Upside: +21,076.47%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $5.00
Upside: +300.00%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $121.41
Upside: +7.08%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $5.34
Upside: -62.55%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.67
Upside: +618.56%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $61.43
Upside: -67.44%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.57
Upside: +534.08%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $30.00
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $6.47
Upside: +116.38%